Identifying & Screening Hits in Drug Discovery 

In today’s high-stakes world of drug discovery, the pressure to uncover effective treatments is reaching new heights. A central hurdle lies in finding promising lead compounds – those critical ‘hits’ capable of interacting with notoriously difficult targets.

That’s where the 2nd Hit ID Summit steps in, designed for forward-thinking discovery teams to enable a focused platform for evaluating and refining hit screening strategies. Through detailed case studies and collaborative discussions, you will gain insights into what’s been tried and what’s to come for validating hits using ASMS and biophysical techniques, and tackling hard-to-drug PPIs, transcription factors, and RNA.

With 60+ medicinal and computational chemists, molecular biologists, biophysicists, and drug discovery decision makers reuniting this September, this forum is your chance to delve into practical strategies for leveraging AI to enhance virtual screening, innovating DELs and fragment-based approaches, as well as building diverse chemical libraries to improve hit-finding success.

In the race to bring novel therapies to market, identifying viable drug candidates remains a priority across many therapeutic indications, highlighting the need for more efficient and effective screening strategies.